Regeneron intends to acquire 23andMe’s Personal Genome Service ® (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million and ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.

Biotechnology firm Regeneron Pharmaceuticals said on Monday it would acquire 23andMe's personal genome service, total health, and research services business lines, and its biobank of customers' ...

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million USD through a bankruptcy auction, and promised to prioritize the ethical use of customers ...

STORY: Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy.It also promised to prioritize the ethical use of customers' DNA ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against Regeneron Pharmaceuticals Inc.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...